Octave Bioscience to Participate in Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Audio By Carbonatix

MENLO PARK, Calif.--(BUSINESS WIRE)--Nov 10, 2025--

Octave Bioscience, Inc., a leading precision care company that is delivering a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, announced today that its management team will be attending the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and participating in a panel discussion on Thursday, November 20, 2025, at 9:00 AM EST at The Westin Grand Central in New York, NY.

About Octave Bioscience, Inc.

Octave Bioscience, Inc. is a commercial stage precision care company pioneering biomarker-driven solutions for neurodegenerative diseases, with initial focus on Multiple Sclerosis, and Parkinson’s Disease in partnership with Michael J. Fox Foundation. Octave’s comprehensive testing solutions provide objective, actionable insights to improve disease monitoring, treatment decisions, and patient outcomes. For more information, visit www.octavebio.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251110583631/en/

CONTACT: Caroline Corner

ICR Healthcare

[email protected]

KEYWORD: CALIFORNIA NEW YORK UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH NEUROLOGY MANAGED CARE RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Octave Bioscience, Inc.

Copyright Business Wire 2025.

PUB: 11/10/2025 04:01 PM/DISC: 11/10/2025 04:01 PM

http://www.businesswire.com/news/home/20251110583631/en